MedTrace Logo

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

NCT03630055 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 930

Last updated 2026-05-05

No results posted yet for this study

Summary

Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.

Conditions

  • Radial Artery Occlusion

Interventions

DRUG

Rivaroxaban 15 MG Oral Tablet [Xarelto]

Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-03
Primary Completion
2025-06-26
Completion
2025-06-26
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03630055 on ClinicalTrials.gov